Related Experiment Videos
Polymorphisms in FcepsilonRI beta chain do not affect IgE-mediated mast cell activation.
Y Furumoto1, S Hiraoka, K Kawamoto
1Allergy Research Center, Department of Immunology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Biochemical and Biophysical Research Communications
|June 30, 2000
Summary
Genetic variations in the FcepsilonRI beta chain do not impact mast cell activation. These findings suggest these specific polymorphisms are unlikely to be major contributors to allergic diseases like asthma.
Area of Science:
- Immunology
- Molecular Biology
Background:
- Genetic polymorphisms in the FcepsilonRI beta chain, involving three amino acid changes (Ile181Leu, Val183Leu, Glu237Gly), are potential candidates linked to allergic disorders.
- Understanding the functional impact of these FcepsilonRI beta chain variants is crucial for elucidating their role in atopy and asthma pathogenesis.
Purpose of the Study:
- To investigate the biological significance of FcepsilonRI beta chain polymorphisms on FcepsilonRI expression and function.
- To determine if specific human FcepsilonRI beta chain variants affect mast cell activation in vitro.
Main Methods:
- Generated four types of transfectants expressing wild-type or mutant mouse beta chains corresponding to human variants.
- Utilized retrovirus-mediated gene transfer into beta chain-deficient mouse-derived mast cells.
- Assessed mast cell activation via beta-hexosaminidase release, intracellular calcium mobilization, and mediator production (cytokines, LTC4) following FcepsilonRI crosslinking.
Main Results:
- No significant functional differences were observed between wild-type and mutant FcepsilonRI beta chain transfectants.
- Mast cell activation markers, including degranulation, calcium signaling, and mediator release, remained comparable across all tested variants.
- The specific amino acid substitutions did not alter FcepsilonRI-mediated mast cell responses in this experimental system.
Conclusions:
- The studied FcepsilonRI beta chain polymorphisms (Ile181Leu, Val183Leu, Glu237Gly) do not appear to significantly affect FcepsilonRI-mediated mast cell activation.
- These results suggest that these particular genetic variations may not be major drivers of allergic diseases such as atopy and asthma, at least within the context of this in vitro mouse model.